FİLİZ GÜLDAVAL, CEYDA ANAR, GULRU POLAT, MELİKE YÜKSEL YAVUZ, AHMET ERGİN ÇAPAR, MELİH BÜYÜKŞİRİN, FATMA DEMİRCİ ÜÇSULAR
Journal of Clinical Practice and Research - 2021;43(3):288-292
Objective: We aimed to evaluate retrospectively the data of patients undergoing bronchial artery embolizatıon (BAE) for massive or non-massive hemoptysis in our clinic and discussed with the literature. Materials and Methods: We retrospectively evaluated patients with acute severe or chronic recurrent hemoptysis admitted to the pulmonology department and submitted to BAE for the purpose of embolization. Results: A total of 52 patients were submitted to BAE, 41 (78.8%) were male, with a mean age 53.7±14.8 years. Hemoptysis was considered severe in 22 (42.3%) patients. Bronchiectasis (other than cystic fibrosis) (n=12; 23.1%) and tuberculosis (TB) sequelae (n=11; 21.2) were the major etiology for hemoptysis. None of our patients developed early or late complications related to the procedure. Hemoptysis recurred in five patients at 12-month follow-up of each patient. There was no significant difference between the amount of hemoptysis and the presence of lesion on computed tomography, active bleeding on bronchoscopy or recurrence. Conclusion: Bronchiectasis (except those associated with cystic fibrosis), TB, and TB sequelae were the major etiologies for hemoptysis. Our results show that BAE is a safe and effective treatment supporting the current literature for acute massive and chronic recurrent hemoptysis.
